Food and Drug Administration officials pushed back Tuesday against claims that their authorization of convalescent blood plasma treatments for Covid-19 had been politicized, as the partisan brushfire obscures several scientific and public-health ramifications of the agency’s decision. The FDA on Sunday authorized antibody-rich convalescent plasma, derived from patients who have survived the virus, as a potentially effective therapy against the new coronavirus. The authorization came after President Trump criticized the agency...

Source: Wall Street Journal August 25, 2020 13:39 UTC